The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 in the Immune System, 2012The Four Horsemen of G2019S
Objective/Rationale:
Using stem cell-derived neurons from individuals with Parkinson’s disease, we have found that dopaminergic neurons carrying the G2019S variant of LRRK2 are abnormally... -
MJFF Research Grant, 2012Investigation of Possible Pathological Changes in Aged LRRK2 Knockout Models
Objective/Rationale:
To determine if there are any pathological changes in either the brain, kidney, lung, spleen, liver, and heart in aged LRRK2 knockout and wild type pre-clinical... -
MJFF Research Grant, 2012Role of LRRK2 in Alpha-Synuclein-Induced Neurodegeneration
Objective/Rationale:
This project seeks to develop a robust and standardized pre-clinical model relevant to late-onset Parkinson’s disease (PD) that will identify clinically viable LRRK2 kinase... -
Therapeutics Development Initiative, 2012Peripheral Administration of XPro1595 in the Pre-clinical 6-OHDA Model of Parkinson's Disease
Objective/Rationale:
Inflammation in the brain is one of the causes of Parkinson’s disease. XPro1595 is a selective inhibitor of soluble TNF that “turns off” inflammation to stop the loss of... -
Rapid Response Innovation Awards, 2012A Pair of Neurotrophic Factor Inducing Drug Candidates
Objective/Rationale:
The brain makes proteins that are required to keep nerve cell alive and healthy. They go down in Parkinson’s disease, and cannot get into the brain when ingested. ... -
LRRK2 Cohort Working Group, 2012LRRK2 Mutations and Cancer Risk
Objective/Rationale:
Two groups have reported a possible association between carrying a LRRK2 mutation and non-skin cancers. In order to determine whether this finding is present in a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.